Navigation Links
Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2011 Results
Date:8/9/2011

including Endu, Sinofuan and Jiebaishu, achieved healthy growth," said Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group. "Changes to government pricing policies have negatively impacted margins for some of our branded generic drugs, including Zailin."

Mr. Ren added, "We continue to make significant investments in R&D to support Simcere's long-term development strategy, including Bicun's overseas clinical research. In July we received approval from the SFDA to conduct clinical trials for our innovative anti-tumor drug Simotinib. Our recently announced joint-venture with Merck & Co., Inc. represents a major step forward in our strategy to cooperate with international partners to address the needs of Chinese patients."

2011 Second Quarter Financial Results Total revenue for the second quarter of 2011 was RMB546.4 million (US$84.4 million), compared to RMB544.6 million for the same period in 2010, representing a year-over-year growth of 0.3%. For the first six months of 2011, total revenue was RMB1,028.6 million (US$158.9 million), representing an increase of 2.5% from RMB1,003.2 million for the same period in 2010.

Revenue from edaravone injection productsunder the brand names Bicun and Yidasheng increased by 12.7% to RMB217.9 million (US$33.7 million) for the second quarter of 2011 from RMB193.3 million for the same period in 2010. Sales of edaravone injection products constituted 39.9% of the Company's total revenue for the second quarter of 2011. For the first six months of 2011, revenue from Bicun and Yidasheng totaled RMB406.7 million (US$62.8 million), which represented an increase of 10.9% from RMB366.7 million for the same period in 2010.

Revenue from Endu,the Company's patented anti-cancer biotech product, increased by 30.3% to RMB70.0 million (US$10.8 million) in the second quarter of 20
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
2. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
3. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
4. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
5. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
6. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
7. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
8. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
9. Simceres Diosmectite API Passes EU-GMP Inspection
10. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
11. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... -- Pfenex Inc. (NYSE MKT: PFNX) today announced the IND ... and is now open and that this program has ... and Human Services (HHS), through the Biomedical Advanced Research ... pleased to have the IND now active for our ... in our company,s partnership with BARDA as we continue ...
(Date:12/19/2014)... 19, 2014  Newport Corporation (NASDAQ: ... has joined the company,s Board of Directors.  Dr. ... a director of Evans Analytical Group, a leading ... analytical services to companies in a wide range ... Evans Analytical Group, Dr. Kadia spent nine years ...
(Date:12/19/2014)... Dec. 19, 2014 In today,s increasingly ... web presence to reflect the needs of a ... must meet the needs of key stakeholders while ... According to recent research by benchmarking ... the participating companies averaged more than $100,000 in ...
Breaking Medicine Technology:Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2Building a Best-in-Class Pharma Global Brand Website 2
... 11, 2012 Bacterin International Holdings, Inc. (NYSE Amex: ... revolutionary bone graft material and antimicrobial coatings for medical applications, ... Markets, 8th Annual Equity Conference. The conference will be held ... on January 17-18, 2012. Bacterin,s chairman and CEO, ...
... Pharmaceuticals announced today that, effective December 22, 2011, it ... Magonate® and ProBarimin QT® products to Valeant International (Barbados) ... North America LLC, to act as distributor of these ... manufactures contract products for a broad customer base, including ...
Cached Medicine Technology:Bacterin to Present at the Noble 8th Annual Equity Conference on January 17, 2012 2Bacterin to Present at the Noble 8th Annual Equity Conference on January 17, 2012 3
(Date:12/22/2014)... 2014 International efforts to ... epidemic are receiving further support from recent ... organizations (NGOs) and other charitable organizations. While ... emergency responders, patients and others can immediately ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... 2014 The Bob Woodruff Foundation ... invested more than $5 million in programs and ... their families. , This includes $1.3 million in ... helping with: veteran entrepreneurship; community impact; vocational training; ... severely injured veterans. , “The needs of those ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Give a ... season, the gift of health and vitality. , For ... its three top-selling anti-aging formulas in special Holiday Wellness ... rush delivery. , Each bottle contains cutting-edge, proven ... that don't work as well as we age. ...
(Date:12/22/2014)... York NY (PRWEB) December 22, 2014 ... that a federal panel of judges has granted a ... in the U.S. District Court, Eastern District of ... issued an order on December 12 to transfer over ... in 22 districts to the Louisiana court for consolidation ...
(Date:12/22/2014)... December 22, 2014 Christmas is days away, ... a fast and easy solution that will please: the ... be purchased from from $25 up to $350," says Kathy ... customer satisfaction and a wide array of skin care products ... and no expiration dates. , Gift delivery past shipping ...
Breaking Medicine News(10 mins):Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4
... separated at the time of diagnosis do not live as ... the conclusion of a new study to be published in ... peer-reviewed journal of the American Cancer Society. The authors of ... with marital separation may compromise an individual,s immune system and ...
... A new technique may help clinicians hone in on a ... cause. The study, led by principal investigator Y.C. ... the American Thoracic Society,s American Journal of Respiratory and ... of fluid in the pleural cavity, can be maddeningly difficult ...
... Pulmonary Fibrosis is not much better than a death ... is less than three years. But researchers at ... a novel gene utilizing genetic and pharmacologic strategies was ... be developed for future testing in humans. The ...
... works best , SUNDAY, Aug. 23 (HealthDay News) -- Medics ... activity when trying to save a person who,s had a ... defibrillation to restart the heart. , But studies now show ... as ordinary cardiopulmonary resuscitation, or CPR. And what,s more, those ...
... ... facility, positioning the company to support defense-related semiconductor manufacturing and development programs. , ... Cherry Hill, NJ (PRWEB) ... Arms Regulations) registered for its Cherry Hill, New Jersey manufacturing facility. ITAR regulates the ...
... root, study finds , FRIDAY, Aug. 21 (HealthDay News) -- ... before they take root in the brain. , That,s the ... rats -- assuming the findings can be applied to humans, ... of Rio Grande do Sul, Brazil, with colleagues at the ...
Cached Medicine News:Health News:Cancer patients who are separated when diagnosed have worse survival rates 2Health News:New technique can help diagnose mesothelioma 2Health News:U-M researchers discover therapeutic target that could help patients with pulmonary fibrosis 2Health News:It's Back to Basics to Save a Life 2Health News:It's Back to Basics to Save a Life 3Health News:International Micro Industries (IMI) is ITAR Registered 2Health News:Dopamine Lets Bad Experiences Linger 2Health News:Dopamine Lets Bad Experiences Linger 3
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Ethicon Endo-Surgery provides disposable handheld instruments that provide reliable, precise performance every time. Our handheld instruments come in 5mm and 10mm sizes....
... The Auto Suture™ ... inclusive of five (5) ... application in a variety ... urologic, colorectal and other ...
The ENDO MINI-RETRACT™ 5 mm instrument has application in a variety of gynecologic, abdominal, urologic, thoracic and endoscopic procedures for temporary retraction of tissue and small tubular ...
Medicine Products: